CA2721683A1 - Polypeptides modifies de facteur ix et leurs utilisations - Google Patents

Polypeptides modifies de facteur ix et leurs utilisations Download PDF

Info

Publication number
CA2721683A1
CA2721683A1 CA2721683A CA2721683A CA2721683A1 CA 2721683 A1 CA2721683 A1 CA 2721683A1 CA 2721683 A CA2721683 A CA 2721683A CA 2721683 A CA2721683 A CA 2721683A CA 2721683 A1 CA2721683 A1 CA 2721683A1
Authority
CA
Canada
Prior art keywords
fix
polypeptide
amino acid
polypeptides
glycosylation sites
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2721683A
Other languages
English (en)
Inventor
Alan Brooks
John E. Murphy
Marian Seto
Xiaoqiao Jiang
Chandra Patel
Uwe Gritzan
Kornelia Kirchner
Ulrich Haupts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Bayer Healthcare LLC
Original Assignee
Bayer Schering Pharma AG
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma AG, Bayer Healthcare LLC filed Critical Bayer Schering Pharma AG
Publication of CA2721683A1 publication Critical patent/CA2721683A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2721683A 2008-04-16 2009-04-16 Polypeptides modifies de facteur ix et leurs utilisations Abandoned CA2721683A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12456708P 2008-04-16 2008-04-16
US61/124,567 2008-04-16
US4596108P 2008-04-17 2008-04-17
US61/045,961 2008-04-17
PCT/US2009/040813 WO2009137254A2 (fr) 2008-04-16 2009-04-16 Polypeptides modifiés de facteur ix et leurs utilisations

Publications (1)

Publication Number Publication Date
CA2721683A1 true CA2721683A1 (fr) 2009-11-12

Family

ID=41265284

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2721683A Abandoned CA2721683A1 (fr) 2008-04-16 2009-04-16 Polypeptides modifies de facteur ix et leurs utilisations

Country Status (17)

Country Link
EP (1) EP2288622A4 (fr)
JP (1) JP2011517951A (fr)
KR (1) KR20110005862A (fr)
CN (1) CN102083856A (fr)
AU (1) AU2009244633A1 (fr)
BR (1) BRPI0910702A2 (fr)
CA (1) CA2721683A1 (fr)
CO (1) CO6311000A2 (fr)
CR (1) CR11737A (fr)
DO (1) DOP2010000311A (fr)
EC (1) ECSP10010551A (fr)
IL (1) IL208718A0 (fr)
MX (1) MX2010011345A (fr)
RU (1) RU2010146387A (fr)
SG (1) SG189790A1 (fr)
SV (1) SV2010003704A (fr)
WO (1) WO2009137254A2 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200804416A (en) * 2006-06-19 2008-01-16 Nautilus Technology Llc Modified coagulation factor IX polypeptides and use thereof for treatment
JP5613876B2 (ja) * 2007-10-15 2014-10-29 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 延長された半減期を備えるヒト第ｉｘ因子変異体
FI3581650T3 (fi) 2008-09-15 2023-03-23 Uniqure Biopharma B V IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi
NZ605348A (en) 2010-07-09 2015-01-30 Biogen Idec Hemophilia Inc Factor ix polypeptides and methods of use thereof
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
AU2013204511B2 (en) * 2010-11-03 2016-03-17 Gc Biopharma Corp. Modified factor ix polypeptides and uses thereof
US9486507B2 (en) 2011-06-10 2016-11-08 Biogen Ma Inc. Pro-coagulant compounds and methods of use thereof
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
US9738884B2 (en) 2012-04-27 2017-08-22 Nihon University Therapeutic agent for epithelial and endothelial injury
EP2877202A4 (fr) 2012-07-25 2016-06-01 Biogen Ma Inc Essai de surveillance de facteur sanguin et utilisations de celui-ci
EP3542861A1 (fr) 2012-09-25 2019-09-25 Bioverativ Therapeutics Inc. Procédés d'utilisation de polypeptides fix
EP2908847B1 (fr) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Procédés d'utilisation d'une dose fixe d'un facteur de coagulation
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
FI2956477T4 (fi) 2013-02-15 2024-04-24 Bioverativ Therapeutics Inc Optimoitu tekijä viii:n geeni
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
EP3048899B1 (fr) 2013-09-25 2021-09-08 Bioverativ Therapeutics Inc. Procédés d'inactivation de virus sur colonne
EP3065769A4 (fr) 2013-11-08 2017-05-31 Biogen MA Inc. Composé de fusion procoagulant
WO2015085276A1 (fr) 2013-12-06 2015-06-11 Biogen Idec Ma Inc. Outils pharmacocinétiques de population et leurs utilisations
EP3083933A1 (fr) 2013-12-20 2016-10-26 Biogen MA Inc. Utilisation de cultures de semences sous perfusion pour améliorer la capacité de production en alimentation programmée de produits biopharmaceutiques et la qualité des produits
TWI700101B (zh) 2014-03-24 2020-08-01 美商百歐維拉提夫治療公司 凍乾之因子ｉｘ調配物
EP3160478A4 (fr) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Gène du facteur ix optimisé
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
PL3411478T3 (pl) 2016-02-01 2022-10-03 Bioverativ Therapeutics Inc. Geny zoptymalizowanego czynnika VIII
CN105695616A (zh) * 2016-04-22 2016-06-22 王冬国 诊断甲状腺癌的分析标志物及其应用
EP3548066A1 (fr) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques
KR20190112763A (ko) 2017-01-31 2019-10-07 바이오버라티브 테라퓨틱스 인크. 인자 ix 융합 단백질 및 이의 제조 및 사용 방법
FR3069540B1 (fr) 2017-07-28 2019-09-13 Universite Claude Bernard Lyon 1 Proteine modifiee avec demi-vie amelioree
SG11202000764RA (en) 2017-08-09 2020-02-27 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
AU2018338608A1 (en) 2017-09-27 2020-04-09 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells
IL277713B2 (en) 2018-04-04 2024-09-01 Sigilon Therapeutics Inc Implantable particles and related methods
US20210145889A1 (en) 2018-04-04 2021-05-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
SG11202010767SA (en) 2018-05-18 2020-11-27 Bioverativ Therapeutics Inc Methods of treating hemophilia a
BR112021002017A2 (pt) 2018-08-09 2021-05-11 Bioverativ Therapeutics Inc. moléculas de ácido nucleico e usos das mesmas para terapia genética não viral
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
WO2020086408A1 (fr) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bioprocédé d'expression génique transitoire basé sur une perfusion à haut rendement
US20220323519A1 (en) 2019-04-17 2022-10-13 Codiak Biosciences, Inc. Compositions of exosomes and aav
WO2021154414A2 (fr) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Thérapie génique pour l'hémophilie b avec un vecteur de capside d'aav chimérique codant pour des polypeptides du facteur ix modifiés
AU2022226969A1 (en) 2021-02-24 2023-09-14 Bluehalo Llc System and method for a digitally beamformed phased array feed
WO2024081309A1 (fr) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Cellules modifiées et éléments implantables pour le traitement d'une maladie
WO2024081310A1 (fr) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Cellules modifiées et éléments implantables pour le traitement d'une maladie

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2638643B1 (fr) * 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
WO1999003496A1 (fr) * 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Facteur ix antihemophilique presentant une activite de coagulation augmentee
HUP0401534A3 (en) * 2001-09-04 2006-01-30 Merck Patent Gmbh Modified factor ix
US20050008580A1 (en) * 2003-04-09 2005-01-13 Wyeth Hemophilia treatment by inhalation of coagulation factors
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
BRPI0417341A (pt) * 2003-12-03 2007-04-17 Neose Technologies Inc fator ix glicopeguilado
TW200804416A (en) * 2006-06-19 2008-01-16 Nautilus Technology Llc Modified coagulation factor IX polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
MX2010011345A (es) 2011-02-23
CO6311000A2 (es) 2011-08-22
JP2011517951A (ja) 2011-06-23
CR11737A (es) 2011-02-07
SG189790A1 (en) 2013-05-31
WO2009137254A2 (fr) 2009-11-12
AU2009244633A1 (en) 2009-11-12
BRPI0910702A2 (pt) 2016-07-05
CN102083856A (zh) 2011-06-01
ECSP10010551A (es) 2010-11-30
EP2288622A2 (fr) 2011-03-02
RU2010146387A (ru) 2012-05-27
KR20110005862A (ko) 2011-01-19
IL208718A0 (en) 2010-12-30
WO2009137254A3 (fr) 2010-01-14
SV2010003704A (es) 2011-02-21
EP2288622A4 (fr) 2012-04-18
DOP2010000311A (es) 2011-02-28

Similar Documents

Publication Publication Date Title
CA2721683A1 (fr) Polypeptides modifies de facteur ix et leurs utilisations
TWI595004B (zh) 經修飾之第九因子多胜肽及其用途
JP5976021B2 (ja) 改変された第ｖｉｉ因子ポリペプチドおよびその使用
US8383388B2 (en) Modified coagulation factor IX polypeptides and use thereof for treatment
EP2108045B1 (fr) Protéines mutantes de fix améliorées destinées à traiter l'hémophilie b
CN108289851B (zh) 长效凝固因子及其产生方法
EP3326642B1 (fr) Facteurs de coagulation a action prolongee et leurs utilizations
KR20110015551A (ko) 제ｉｘ인자의 부위-지정 변형
US8513386B2 (en) FVIII-independent FIX-mutant proteins for hemophilia a treatment
SG178119A1 (en) Modified factor ix polypeptides and uses thereof
US20120178693A1 (en) Cofactors for Thrombin Activation of Factor VII and Uses Thereof
US11491212B1 (en) Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20150416